Anna-Barbara Moscicki, MD
is Professor of Pediatrics at UCLA, Division Chief of Adolescent and Young Adult Medicine, and Associate Vice Chair of Clinical Research, Department of Pediatric. Dr. Moscicki is Past President for the ASCCP. Dr. Moscicki’s career has focused on adolescent gynecology and sexually transmitted infection research with a specific focus in Human Papillomavirus, HIV infection and mucosal immunology. Dr. Moscicki has been the principal investigator of a natural history study of HPV in adolescents and young women since 1990, one of the longest running HPV cohorts. Her work was highly influential in forming the new cervical cancer screening guidelines and triage of abnormal cytology in young women. Her recent work focuses on mucosal immunology and the vaginal microbiota. She has been involved in numerous clinical trials including vaginal microbiocides and an ongoing one dose HPV vaccine trial. She is also involved in health outcomes in perinatally HIV infected children including HPV vaccine efficacy, sexual risk behaviors, substance use, oral health, microbiomes, and HPV infections and has worked with numerous Networks on HIV disease in children and adolescents including Adolescent Medicine HIV/AIDS Research Network, Adolescent Therapeutic Network, IMPAACT and PHACS. She has over 150 publications and she serves on numerous national and international committees, including the W.H.O., N.I.H., ASCCP, and the American Cancer Society.
is Professor of Pediatrics at UCLA, Division Chief of Adolescent and Young Adult Medicine, and Associate Vice Chair of Clinical Research, Department of Pediatric. Dr. Moscicki is Past President for the ASCCP. Dr. Moscicki’s career has focused on adolescent gynecology and sexually transmitted infection research with a specific focus in Human Papillomavirus, HIV infection and mucosal immunology. Dr. Moscicki has been the principal investigator of a natural history study of HPV in adolescents and young women since 1990, one of the longest running HPV cohorts. Her work was highly influential in forming the new cervical cancer screening guidelines and triage of abnormal cytology in young women. Her recent work focuses on mucosal immunology and the vaginal microbiota. She has been involved in numerous clinical trials including vaginal microbiocides and an ongoing one dose HPV vaccine trial. She is also involved in health outcomes in perinatally HIV infected children including HPV vaccine efficacy, sexual risk behaviors, substance use, oral health, microbiomes, and HPV infections and has worked with numerous Networks on HIV disease in children and adolescents including Adolescent Medicine HIV/AIDS Research Network, Adolescent Therapeutic Network, IMPAACT and PHACS. She has over 150 publications and she serves on numerous national and international committees, including the W.H.O., N.I.H., ASCCP, and the American Cancer Society.